Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise

No Thumbnail Available

Authors

Nauck, M. A.
Stewart, M. W.
Perkins, C.
Jones-Leone, A.
Yang, F.
Perry, C.
Reinhardt, R. R.
Rendell, M.

Issue Date

2016

Type

Journal Article

Language

eng_US

Keywords

Research Projects

Organizational Units

Journal Issue

Alternative Title

Abstract

Description

Citation

Nauck, M. A.; Stewart, M. W.; Perkins, C.; Jones-Leone, A.; Yang, F.; Perry, C.; Reinhardt, R. R.; Rendell, M. (2016). Efficacy and Safety of Once-Weekly GLP-1 Receptor Agonist Albiglutide (HARMONY 2): 52 Week Primary Endpoint Results from a Randomised, Placebo-Controlled Trial in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Diet and Exercise. Diabetologia, 2016 February, 59(2):266-274. doi: http://doi.org/10.1007/s00125-015-3795-1

Publisher

License

Journal

Volume

Issue

URI

http://hdl.handle.net/10504/84773

PubMed ID

26577795

DOI

ISSN

1432-0428
0012-186X

EISSN

Collections

Faculty Bibliography Database